Antiproliferative effects of 2-methoxyestradiol alone and in combination with chemotherapeutic agents on human endometrial cancer cells

European Journal of Gynaecological Oncology

Volumn 30, Issue 3, 2009, Pages 275-280

  Chen, C H ^a   Lee, W J ^a   Chang, T C ^a   Chen, R J ^a   Chien, C H ^b   Chow, S N ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

2 methoxyestradiol; Endometrial cancer; Paclitaxel; Proliferation

Indexed keywords

2 METHOXYESTRADIOL; CISPLATIN; DOXORUBICIN; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOXORUBICIN; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOMETRIAL NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 67649768664     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A. et al.: "Cancerstatistics, 2005". CA Cancer J. Clin., 2005, 55, 10.
2. Levine D.A., Hoskins W.J.: "Update in the management of endometrial cancer". Cancer J., 2002, 8 (suppl. 1), S31.
3. Elit L., Hirte H.: "Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer". Curr. Opin. Obstet. Gynecol., 2002, 14, 67. (Pubitemid 34177910)
4. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P. et al.: "The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth". Nature, 1994, 368, 237. (Pubitemid 24108838)
5. Carothers A.M., Hughes S.A., Ortega D., Bertagnolli M.M.: "2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells". Cancer Lett., 2002, 187, 77. (Pubitemid 35279335)
6. Qanungo S., Basu A., Das M., Haldar S.: "2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells". Oncogene, 2002, 21, 4149. (Pubitemid 34712882)
7. Li L., Heldin N.E., Grawe J., Ulmsten U., Fu X.: "Induction of apoptosis or necrosis in human endometrial carcinoma cells by 2-methoxyestradiol". Anticancer Res., 2004, 24, 3983. (Pubitemid 40468697)
8. Lakhani N.J., Sarkar M.A., Venitz J., Figg W.D.: "2- Methoxyestradiol, a promising anticancer agent". Pharmacotherapy, 2003, 23, 165.
9. Sato F., Fukuhara H., Basilion J.R: "Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo". Neoplasia, 2005, 7, 838.
10. Ireson C.R., Chander S.K., Purohit A., Perera S., Newman S.P., Parish D. et al.: "Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents". Br. J. Cancer, 2004, 90, 932. (Pubitemid 38406609)
11. Lin H.L., Liu T.Y., Wu C.W., Chi C.W.: "2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells". Cancer, 2001, 92, 500.
12. Zoubine M.N., Weston A.P., Johnson D.C., Campbell D.R., Banerjee S.K.: "2-methoxyestradiol-induced growth suppression and lethality in estrogen-responsive MCF-7 cells may be mediated by down regulation of p34cdc2 and cyclin B1 expression". Int. J. Oncol, 1999, 15, 639.
13. Ray G., Dhar G., Van Veldhuizen P.J., Banerjee S., Saxena N.K., Sengupta K. et al.: "Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways". Biochemistry, 2006, 45, 3703.
14. Han G.Z., Liu Z.J., Shimoi K., Zhu B.T: "Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer". Cancer Res., 2005, 65, 387.
15. Mueck A.O., Seeger H., Wallwiener D., Huober J.: "Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations". Eur. J. Gynaecol. Oncol., 2004, 25, 699. (Pubitemid 39576946)
16. Li L., Yu F., Wu X., Cheng J., Ulmsten U., Fu X.: "Effects of 2-methoxyestradiol on endometrial carcinoma xenografts". J. Cancer Res. Clin. Oncol., 2007, 133, 315. (Pubitemid 46723499)
17. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R.J.: "Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol". Cancer Res., 1997, 57, 81. (Pubitemid 27021522)
18. Pribluda V.S., Gubish E.R. Jr., Lavallee T.M., Treston A., Swartz G.M., Green S.J.: "2-methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate". Cancer Metastasis Rev., 2000, 19, 173. (Pubitemid 32004707)
19. Chauhan D., Catley L., Hideshima T., Li G., Leblanc R., Gupta D. et al.: "2-methoxyestradiol overcomes drug resistance in multiple myeloma cells". Blood, 2002, 100, 2187. (Pubitemid 35001255)
20. Wang T.H., Wang H.S., Soong Y.K.: "Paclitaxel-induced cell death: where the cell cycle and apoptosis come together". Cancer, 2000, 88, 2619.
21. Dai D., Holmes A.M., Nguyen T., Davies S., Theele D.P., Verschraegen C. et al..: "A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer". Cancer Res., 2005, 65, 9517. (Pubitemid 41508022)
22. Kamath K., Okouneva T., Larson G., Panda D., Wilson L., Jordan M.A.: "2-methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules". Mol. Cancer Their., 2006, 5, 2225. (Pubitemid 44530459)
23. Sweeney C., Liu G., Yiannoutsos C., Kolesar J., Horvath D., Staab M.J. et al.: "A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer". Clin. Cancer Res., 2005, 11, 6625. (Pubitemid 41339003)
24. James J., Murry D.J., Treston A.M., Storniolo A.M., Sledge G.W., Sidor C. et al.: "Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with ddcetaxel in patients with locally recurrent or metastatic breast cancer". Invest. New Drugs, 2007, 25, 41. (Pubitemid 44657641)